These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 34948413)

  • 1. Duodenal Dysbiosis and Relation to the Efficacy of Proton Pump Inhibitors in Functional Dyspepsia.
    Wauters L; Tito RY; Ceulemans M; Lambaerts M; Accarie A; Rymenans L; Verspecht C; Toth J; Mols R; Augustijns P; Tack J; Vanuytsel T; Raes J
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proton Pump Inhibitors Reduce Duodenal Eosinophilia, Mast Cells, and Permeability in Patients With Functional Dyspepsia.
    Wauters L; Ceulemans M; Frings D; Lambaerts M; Accarie A; Toth J; Mols R; Augustijns P; De Hertogh G; Van Oudenhove L; Tack J; Vanuytsel T
    Gastroenterology; 2021 Apr; 160(5):1521-1531.e9. PubMed ID: 33346007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Proton Pump Inhibitors on the Gastric Mucosa-Associated Microbiota in Dyspeptic Patients.
    Paroni Sterbini F; Palladini A; Masucci L; Cannistraci CV; Pastorino R; Ianiro G; Bugli F; Martini C; Ricciardi W; Gasbarrini A; Sanguinetti M; Cammarota G; Posteraro B
    Appl Environ Microbiol; 2016 Nov; 82(22):6633-6644. PubMed ID: 27590821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proton pump inhibitors enhance intestinal permeability via dysbiosis of gut microbiota under stressed conditions in mice.
    Takashima S; Tanaka F; Kawaguchi Y; Usui Y; Fujimoto K; Nadatani Y; Otani K; Hosomi S; Nagami Y; Kamata N; Taira K; Tanigawa T; Watanabe T; Imoto S; Uematsu S; Fujiwara Y
    Neurogastroenterol Motil; 2020 Jul; 32(7):e13841. PubMed ID: 32319196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel concepts in the pathophysiology and treatment of functional dyspepsia.
    Wauters L; Talley NJ; Walker MM; Tack J; Vanuytsel T
    Gut; 2020 Mar; 69(3):591-600. PubMed ID: 31784469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations among the Duodenal Ecosystem, Gut Microbiota, and Nutrient Intake in Functional Dyspepsia.
    Kim SH; Choi Y; Oh J; Lim EY; Lee JE; Song EJ; Nam YD; Kim H
    Gut Liver; 2024 Jul; 18(4):621-631. PubMed ID: 38031491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duodenal microbiota dysbiosis in functional dyspepsia and its potential role of the duodenal microbiota in gut-brain axis interaction: a systematic review.
    Zhang X; Chen L; Zhang T; Gabo R; Wang Q; Zhong Z; Yao M; Wei W; Su X
    Front Microbiol; 2024; 15():1409280. PubMed ID: 39165566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proton pump inhibitor monotherapy is effective to attenuate dyspepsia symptoms associated with gastroesophageal reflux disease: a multicenter prospective observational study.
    Isshi K; Matsuhashi N; Joh T; Higuchi K; Iwakiri K; Kamiya T; Manabe N; Ogawa M; Arihiro S; Haruma K; Nakada K
    J Gastroenterol; 2019 Jun; 54(6):492-500. PubMed ID: 30673836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of acotiamide in combination with esomeprazole for functional dyspepsia refractory to proton-pump inhibitor monotherapy.
    Mayanagi S; Kishino M; Kitagawa Y; Sunamura M
    Tohoku J Exp Med; 2014 Nov; 234(3):237-40. PubMed ID: 25382232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Proton Pump Inhibitors on the Small Bowel and Stool Microbiomes.
    Weitsman S; Celly S; Leite G; Mathur R; Sedighi R; Barlow GM; Morales W; Sanchez M; Parodi G; Villanueva-Millan MJ; Rezaie A; Pimentel M
    Dig Dis Sci; 2022 Jan; 67(1):224-232. PubMed ID: 33534012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised clinical trial: sustained response to PPI treatment of symptoms resembling functional dyspepsia and irritable bowel syndrome in patients suffering from an overlap with erosive gastro-oesophageal reflux disease.
    Mönnikes H; Schwan T; van Rensburg C; Straszak A; Theek C; Sander P; Lühmann R
    Aliment Pharmacol Ther; 2012 Jun; 35(11):1279-89. PubMed ID: 22486552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review article: Functional dyspepsia-a gastric disorder, a duodenal disorder or a combination of both?
    Broeders BWLCM; Carbone F; Balsiger LM; Schol J; Raymenants K; Huang I; Verheyden A; Vanuytsel T; Tack J
    Aliment Pharmacol Ther; 2023 Apr; 57(8):851-860. PubMed ID: 36859629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: Acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor.
    Takeuchi T; Takahashi Y; Kawaguchi S; Ota K; Harada S; Kojima Y; Sakamoto H; Kuramoto T; Kojima K; Sanomura M; Hoshimoto M; Higashino T; Itabashi T; Takada K; Sakaguchi M; Tominaga K; Kusano M; Higuchi K
    J Gastroenterol Hepatol; 2018 Mar; 33(3):623-630. PubMed ID: 28865098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the altered duodenal microenvironment in functional dyspepsia.
    Ceulemans M; Wauters L; Vanuytsel T
    Curr Opin Pharmacol; 2023 Jun; 70():102363. PubMed ID: 36963152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gut Microbiota Composition Before and After Use of Proton Pump Inhibitors.
    Hojo M; Asahara T; Nagahara A; Takeda T; Matsumoto K; Ueyama H; Matsumoto K; Asaoka D; Takahashi T; Nomoto K; Yamashiro Y; Watanabe S
    Dig Dis Sci; 2018 Nov; 63(11):2940-2949. PubMed ID: 29796911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations to the duodenal microbiota are linked to gastric emptying and symptoms in functional dyspepsia.
    Shanahan ER; Kang S; Staudacher H; Shah A; Do A; Burns G; Chachay VS; Koloski NA; Keely S; Walker MM; Talley NJ; Morrison M; Holtmann GJ
    Gut; 2023 May; 72(5):929-938. PubMed ID: 36167662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is administration of proton pump inhibitors in functional dyspepsia worth the risk of developing gastric cancer: a Markov model to bridge the gap between scientific evidence and clinical practice.
    Broide E; Eindor-Abarbanel A; Shirin H; Richter V; Matalon S; Leshno M
    BMJ Open; 2020 Feb; 10(2):e031091. PubMed ID: 32051298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased Duodenal Eosinophil Degranulation in Patients with Functional Dyspepsia: A Prospective Study.
    Du L; Shen J; Kim JJ; Yu Y; Ma L; Dai N
    Sci Rep; 2016 Oct; 6():34305. PubMed ID: 27708358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of a Proton Pump Inhibitor on the Duodenum Microbiome of Gastric Ulcer Patients.
    Lim JH; Shin J; Park JS
    Life (Basel); 2022 Sep; 12(10):. PubMed ID: 36294939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers for oralization during long-term proton pump inhibitor therapy predict survival in cirrhosis.
    Horvath A; Rainer F; Bashir M; Leber B; Schmerboeck B; Klymiuk I; Groselj-Strele A; Durdevic M; Freedberg DE; Abrams JA; Fickert P; Stiegler P; Stadlbauer V
    Sci Rep; 2019 Aug; 9(1):12000. PubMed ID: 31427714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.